{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-116651","form_type":"8-K","ticker":"MC","cik":"0001596967","company_name":"Moelis & Co","filed_at":"2024-10-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.918707+00:00","generated_at":"2026-05-30T11:05:35.121295+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Moelis Q3 adjusted EPS $0.22 vs -$0.15; revenue up 1% to $280.7M; declares $0.60 dividend","bullets":["Q3 GAAP revenue $273.8M, adjusted $280.7M (+1% YoY); GAAP diluted EPS $0.22, adjusted $0.22.","Nine-month adjusted revenue $762.8M (+18% YoY); adjusted diluted EPS $0.63 vs ($0.14) loss.","Board declared $0.60/share quarterly dividend, payable Dec 2, record Nov 4.","Cash & short-term investments $297.7M; no debt or goodwill on balance sheet.","Year-to-date hired 8 managing directors (incl. a Biotech MD) and promoted 7 to MD."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-116651","json":"https://secwatch.observer/filing/0000950170-24-116651.json","markdown":"https://secwatch.observer/filing/0000950170-24-116651.md","text":"https://secwatch.observer/filing/0000950170-24-116651.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1596967/000095017024116651/0000950170-24-116651-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1596967/000095017024116651/mc-20241023.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T11:05:35.121295+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}